Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura

In 2021, the world experienced the most extensive vaccination campaign to defeat COVID-19. Many cases of idiopathic thrombocytopenia have been reported following injections of SARS-Cov-2 mRNA vaccine. We present the case of a 73-year-old woman with de novo ITP after a first injection of SARS-Cov-2 mRNA vaccine (Moderna vaccine) who experienced a successful rechallenge of SARS-Cov-2 mRNA vaccine (Pfizer vaccine) a few months later.

Automated summary

This article presents a case of a 73-year-old woman who developed de novo immune thrombocytopenia purpura (ITP) after the first dose of SARS-Cov-2 mRNA vaccine (Moderna vaccine), but successfully underwent a rechallenge with SARS-Cov-2 mRNA vaccine (Pfizer vaccine) a few months later.